Interview with Thomas D. Ingolia of HEPI

Health Enhancement Products, Inc. (OTCBB: HEPI) is a nutraceutical company specializing in the creation of safe, effective products to enhance and strengthen the immune system, as well as provide additional tangible health benefits. Grounded in the latest research, Health Enhancement Products, Inc. (HEPI) has developed ProAlgaZyme, a supplement manufactured from 100% pure, all-natural ingredients. Unlike many supplements that make inflated and unsubstantiated claims, ProAlgaZyme has been demonstrated through clinical testing to reduce total cholesterol and raise HDL (“good cholesterol”) levels, and improve other blood markers. The Company manufactures and distributes ProAlgaZyme, and through its wholly owned subsidiary, HEPI Pharmaceuticals, is actively developing pharmaceutical applications for ProAlgaZyme and other health products to bring to market.

Listen now! (3:07min / 2.9MB)

Interview with Vipul Dev of HLUN

HEALTHeUNIVERSE, Inc. (OTC: HLUN) is a biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products. In particular, the Company is actively engaged in the research and development of cutting-edge non-embryonic stem cell and regenerative medicine therapies for use in plastic, reconstructive, orthopedic, vascular and cardiac surgery. Healtheuniverse is positioning itself to be the first to commercialize the use of regenerative medicine for highly lucrative plastic and reconstructive surgery applications.

Listen now! (3:49min / 3.5MB)

Interview with Scott Cramer of SKBI

Skystar Bio-Pharmaceutical Company (OTCBB: SKBI) has become a high-tech enterprise engaged in the research, development, production, marketing and sales of bio-pharmaceutical and veterinary products in China. Among the company’s several product lines and more than 70 products is the DLV chicken vaccine for the prevention of avian coccidiosis disease. Skystar Bio-Pharmaceutical has an extensive distribution network in the People’s Republic of China and has begun distribution outside the PRC. Most importantly, Skystar is on extremely solid financial footing, achieving superb revenue and income growth levels over the last three years. Skystar is a rarity in the small cap market, with strong revenues and substantial net income levels, resulting in a P/E Ratio (ttm) of 12, well below the Industry P/E of 28.

Listen now! (3:06min / 2.8MB)